|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-11-20
|
|
pubmed:abstractText |
Mycophenolate sodium (MPS) was designed to reduce the gastrointestinal side effects of mycophenolic acid. The aim of our study was to determine the safety and efficacy of MPS in de novo renal transplant recipients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0041-1345
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2730-2
|
|
pubmed:meshHeading |
pubmed-meshheading:18021971-Adult,
pubmed-meshheading:18021971-Creatinine,
pubmed-meshheading:18021971-Cyclosporine,
pubmed-meshheading:18021971-Female,
pubmed-meshheading:18021971-Follow-Up Studies,
pubmed-meshheading:18021971-Glomerular Filtration Rate,
pubmed-meshheading:18021971-Humans,
pubmed-meshheading:18021971-Immunosuppressive Agents,
pubmed-meshheading:18021971-Isoantibodies,
pubmed-meshheading:18021971-Kidney Failure, Chronic,
pubmed-meshheading:18021971-Kidney Transplantation,
pubmed-meshheading:18021971-Male,
pubmed-meshheading:18021971-Middle Aged,
pubmed-meshheading:18021971-Mycophenolic Acid,
pubmed-meshheading:18021971-Prospective Studies,
pubmed-meshheading:18021971-Reoperation,
pubmed-meshheading:18021971-Safety
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Results of a 6-month, multicenter, open-label, prospective study concerning efficacy and safety of mycophenolate sodium in de novo kidney transplant recipients.
|
|
pubmed:affiliation |
Department of Immunology, Transplant Medicine and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
